Authors: SOUMERAI SB ROSSDEGNAN D FORTESS EE WALSER BL

Citation: Sb. Soumerai et al., DETERMINANTS OF CHANGE IN MEDICAID PHARMACEUTICAL COST-SHARING - DOESEVIDENCE AFFECT POLICY, The Milbank quarterly, 75(1), 1997, pp. 11

Authors: ROSSDEGNAN D SOUMERAI SB FORTESS EE GURWITZ JH

Citation: D. Rossdegnan et al., WITHDRAWAL OF A DRUG FROM THE MARKET - WHAT SHOULD THE PRESCRIBER DO, JAMA, the journal of the American Medical Association, 272(16), 1994, pp. 1253-1253

Authors: SOUMERAI SB ROSSDEGNAN D FORTESS EE ABELSON J

Citation: Sb. Soumerai et al., A CRITICAL ANALYSIS OF STUDIES OF STATE DRUG REIMBURSEMENT POLICIES -RESEARCH IN NEED OF DISCIPLINE, The Milbank quarterly, 71(2), 1993, pp. 217-252

Authors: ROSSDEGNAN D SOUMERAI SB FORTESS EE GURWITZ JH

Citation: D. Rossdegnan et al., EXAMINING PRODUCT RISK IN CONTEXT - MARKET WITHDRAWAL OF ZOMEPIRAC ASA CASE-STUDY, JAMA, the journal of the American Medical Association, 270(16), 1993, pp. 1937-1942